The Borrowed Bench: Who Actually Runs Quality Across Four Advanced Modalities
Quality leadership in radiopharma, ADC and cell and gene therapy was not grown inside those modalities. It was imported from adjacent pharma benches. This briefing maps all four benches, with mature biologics as the baseline, and measures how much of a leader's career actually sits inside the modality they now sign off.
What this report answers
- How many people have genuinely run quality in radiopharma, ADC or cell and gene therapy?
- How much of an advanced-modality quality leader's career was spent inside that modality?
- Where did the last two years of quality hires in each modality actually come from?
- Which failure modes does a borrowed quality bench not yet have scar tissue for?
- How thin is the bench measured against the sites currently being built?
- How early does a quality search have to start if the bench is this concentrated?
82%
of radiopharma quality leaders hired in the last two years came from outside radiopharma, on ProGen Search's mapping - the figure the briefing builds its argument around.
4.4
quality leaders per new radiopharma manufacturing site over the 2022-2026 window, which the briefing presents as its own mapping rather than an audited figure.
What the analysis establishes
Four benches, sized and bounded
The briefing sizes the quality leadership bench in each of the four modalities from a single deduped population, one person per row, using an identical role filter and seniority floor throughout. It then marks where the data can be trusted: North America and EMEA are fully represented, APAC is treated as unobserved and quarantined out of every comparison rather than reported thin.
Career depth against modality depth
This is the centre of the report. It separates total years in pharmaceutical quality from the years spent inside the modality a leader now signs off, and scales all four benches to a common maximum so the two measures can be read side by side. The exhibit establishes that career depth and modality depth are not the same variable, and that they diverge sharply by modality.
Grew its own against borrowed
The briefing traces the cause by looking only at leaders who entered their current seat within the last 24 months, and splitting them by whether they came from inside the modality or from outside it. The split explains why one modality reads differently from the other three, and what four decades of commercial scale bought biologics that the newer fields did not have time to buy.
An inspection risk rather than a CV gap
Four modality-specific failure modes are set out - the demands a standard biologics career never had to meet, and the areas radiopharma sites get written up on. These are read against how long each bench has actually been in seat, and against the working minimum time a quality leader needs to build and defend the system an inspection tests.
The bench against the build, and how clustered it is
Headcount is measured against work rather than in isolation: distinct manufacturing facilities announced, under construction or commissioned across a 48-month window, with the bench divided across them. A second measure shows what share of each bench sits inside its two and its five largest employers, which is what determines whether a buildout is recruiting from a pool or from a short list.
Two routes if you are building
The closing section narrows an operator's options to two, states the binding constraint on each, and is explicit that both are search problems and both are timeline decisions taken at facility-planning stage rather than at commissioning. The throughline is that a leader can be imported in a quarter, but the modality years cannot be.
How it was built
ProGen Search's own mapping of quality leadership across every company in each of the four modalities, current as of 2026, deduped to one person per row. The role filter - Head, VP and Director of Quality or QA, and Chief Quality Officer - and the seniority floor were applied identically to all four. Big pharma was excluded from the radiopharma and ADC cohorts to isolate pure-play dynamics; CDMOs are included, since that is where most inspection exposure sits. New sites were verified via public PR and capital-expenditure filings. Populations, ratios, tenures and concentration measures are stated as ProGen's estimates rather than audited figures. APAC is excluded as under-observed, and completed-tenure differences are presented as observation rather than cause.
Written for operators standing up radiopharma, ADC or cell and gene therapy manufacturing, for quality, MSAT and technical operations leadership, and for boards and investors underwriting an advanced-modality buildout timeline.
Contents
- The Finding in One Line
- Four Benches, Four Very Different Shapes
- The Experience Is Real. The Modality Experience Is Not.
- Grew Its Own vs Borrowed
- An Inspection Risk, Not a CV Gap
- The Bench Against the Build
- A Small, Clustered Pool
- On Tenure and Churn, Honestly
- What This Means If You Are Building
- Methodology and Caveats
Regulators referenced
FDA, NRC
The full 18-page briefing is free. Tell us where to send it and it downloads immediately.